NCT04217512RecruitingPhase 3
Pantoprazole in Cisplatin Nephrotoxicity
Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer
Source: ClinicalTrials.gov · Last updated 3 Jan 2020 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Pantoprazole in Cisplatin Nephrotoxicity
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 29 Dec 2019
- Start date
- 1 May 2019
- Primary completion date
- 1 Dec 2030
- Lead sponsor
- Sherief Abd-Elsalam
- Diseases
- Head and neck cancer, Childhood cancers
- NCT number
- NCT04217512
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 60
- From 1 May 2019 to the primary completion date, 1 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- GFR less than 59.
Other
- DM
- Elevated liver enzymes more than 3 fold.
Who the study is looking for
- Patients with head and neck cancer
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sherief Abd-Elsalam Coordinator of this site? Confirm its status | Tanta | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.